RxDoctor Payments Data

Lon Castle, MD

Cardiovascular Disease · Cleveland, OHNPI 1609818731

Payments from drug & device makers

$36,162in general payments, 2019–2025

Across 97 payments — averaging $372.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$11K
  • Johnson & Johnson$10K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$7K
  • Biomerieux Inc$3K
  • Illumina, Inc.$2K
  • Boston Scientific$528
  • plus $2K from 14 others

What the payments were for

  • Speaking & faculty fees$28,98080%
  • Travel & lodging$1,6585%
  • Food & beverage$4,91314%
  • Education$170%
  • Gifts$5812%
  • Entertainment$130%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,162 in reported general payments places this provider in the 85th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$53,804
Medicare patients
908
Services billed
1,677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban346$462,741
XareltoRivaroxaban127$173,441
Dofetilide245$59,078
Flecainide Acetate282$15,045
Metoprolol Succinate410$6,999
Nebivolol Hcl81$4,045
Amiodarone Hcl66$2,258
Diltiazem 24hr Er (Cd)Diltiazem Hcl45$1,374
Propafenone Hcl11$891
Carvedilol59$801
Bisoprolol Fumarate31$730
Verapamil ErVerapamil Hcl15$686
SotalolSotalol Hcl42$605
Atenolol59$573
Digoxin24$572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$143$462,741346 claims
Johnson & JohnsonXarelto$10,381$173,441127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →